Claritev (NYSE:CTEV) Major Shareholder Purchases 13,587 Shares of Stock

Claritev (NYSE:CTEV – Get Free Report) major shareholder Ares Management Llc purchased 13,587 shares of the stock in a transaction dated Wednesday, November 11th. The shares were purchased at an average cost of $28.73 per share, for a total transaction of $390,354.51. Following the transaction, the insider owned 2,063,105 shares in the company, valued at approximately $59,273,006.65. The trade was a 0.66% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ares Management Llc also recently made the following trade(s):

  • On Tuesday, November 10th, Ares Management Llc acquired 65,579 shares of Claritev stock. The shares were purchased at an average price of $26.14 per share, with a total value of $1,714,235.06.
  • On Monday, November 9th, Ares Management Llc acquired 50,000 shares of Claritev stock. The shares were purchased at an average price of $24.42 per share, with a total value of $1,221,000.00.
  • On Monday, October 26th, Ares Management Llc bought 20,834 shares of Claritev stock. The shares were purchased at an average cost of $24.07 per share, for a total transaction of $501,474.38.
  • On Friday, October 23rd, Ares Management Llc bought 50,000 shares of Claritev stock. The stock was purchased at an average price of $23.53 per share, for a total transaction of $1,176,500.00.

Claritev Stock Performance

NYSE:CTEV traded down $1.80 on Monday, hitting $25.02. The stock had a trading volume of 152,295 shares, compared to its average volume of 312,186. The company has a fifty day moving average price of $26.18 and a two-hundred day moving average price of $25.46. Claritev has a 1-year low of $11.50 and a 1-year high of $55.50.

Claritev (NYSE:CTEV – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported $1.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.68) by $5.45. The firm had revenue of $268.31 million for the quarter. Analysts forecast that Claritev will post -15.02 EPS for the current year.

Hedge Funds Weigh In On Claritev

A number of hedge funds have recently made changes to their positions in CTEV. Public Investment Fund purchased a new stake in Claritev in the second quarter valued at approximately $43,703,438. Bank of America Corp DE lifted its stake in Claritev by 146.6% during the first quarter. Bank of America Corp DE now owns 97,795 shares of the company’s stock worth $1,598,000 after purchasing an additional 58,133 shares in the last quarter. Entropy Technologies LP acquired a new position in Claritev during the third quarter worth $265,000. Marshall Wace LLP boosted its position in shares of Claritev by 1,569.2% during the third quarter. Marshall Wace LLP now owns 225,890 shares of the company’s stock worth $4,782,000 after buying an additional 212,357 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in shares of Claritev during the second quarter worth $245,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CTEV. Piper Sandler reiterated an “overweight” rating and issued a $73.00 price objective on shares of Claritev in a research report on Wednesday, August 12th. Wells Fargo & Company upped their price target on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Citigroup reiterated a “buy” rating and set a $45.00 price target (up from $40.00) on shares of Claritev in a report on Monday, August 10th. Wall Street Zen raised Claritev from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a report on Monday, September 21st. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

Check Out Our Latest Analysis on CTEV

Claritev Company Profile

(Get Free Report)

Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.

Read More

Insider Buying and Selling by Quarter for Claritev (NYSE:CTEV)

Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.